Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB
Condition: Tuberculosis, Multidrug-Resistant Interventions: Drug: Delamanid; Drug: Levofloxacin; Drug: Bedaquiline; Drug: Clofazimine; Drug: Linezolid; Combination Product: WHO approved MDR-TB treatment regimens Sponsors: Boston University; United States Department of Defense; Novartis Pharmaceuticals; Pfizer; Otsuka Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bedaquiline | Levaquin | Linezolid | Multidrug Resistance | Pfizer | Research | Tuberculosis | Zyvox